AMAG 2011 Guidance Disappoints, J.P. Morgan Reports

AMAG Pharmaceuticals, Inc.

has provided an update and pre-announces 4Q10 Feraheme revenues of $14.5- 15.5M inline with expectations, J.P. Morgan reports. “The company also provided 2011 Feraheme revenue guidance of $55-60M, which was somewhat disappointing (cons: $74M and JPMe: $94M),” J.P. Morgan writes. “However, the company anticipated a 50% increase in provider demand in the CKD segment for 2011.” J.P. Morgan said that although it is disappointed by 2011 guidance, “we believe it lowers the bar and we maintain our Overweight rating.” AMAG Pharmaceuticals currently trades at $16.93.